Nis793 (Not yet branded)
Other Medications
Description
NIS793 is an anti-TGF-? (transforming growth factor-beta) monoclonal antibody being developed for the treatment of metastatic colorectal cancer. This targeted therapy is designed to block TGF-? signaling, which plays a crucial role in tumor progression, immune suppression, and metastasis in various solid tumors including CRC. NIS793 has been tested in combination with standard-of-care therapies for second-line treatment of metastatic colorectal cancer, as well as in combination with the PD-1 inhibitor spartalizumab (PDR001) across multiple tumor types.
Mechanism of Action
NIS793 functions by binding to and neutralizing TGF- , a cytokine that promotes tumor growth through multiple mechanisms including suppression of anti-tumor immune responses, promotion of epithelial-to-mesenchymal transition, and enhancement of tumor cell invasion and metastasis. By blocking TGF-? signaling, NIS793 aims to restore immune surveillance capabilities and reduce the tumor's ability to evade the immune system. The combination with immunotherapy agents like PD-1 inhibitors is designed to enhance the overall anti-tumor immune response.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.